Scarica l'app Stockscreener
737.77
0.43%
-5.35
Precedente Chiudi:
$743.12
Aprire:
$735.46
Volume 24 ore:
36,475
Relative Volume:
0.10
Capitalizzazione di mercato:
$45.75B
Reddito:
$4.16B
Utile/perdita netta:
$1.29B
Rapporto P/E:
37.67
EPS:
19.5837
Flusso di cassa netto:
$734.26M
1 W Prestazione:
+6.80%
1M Prestazione:
-2.23%
6M Prestazione:
-6.53%
1 anno Prestazione:
+26.78%
Intervallo 1D:
$735.46
$741.22
Intervallo di 1 settimana:
$690.85
$751.92
Portata 52W:
$510.06
$934.62
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX vs VRTX, REGN, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
737.09 | 46.12B | 4.16B | 1.29B | 734.26M | 19.58 |
VRTX
Vertex Pharmaceuticals Inc
|
443.11 | 113.62B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.10 | 82.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.21 | 43.60B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
160.92 | 35.54B | 606.42M | -1.28B | -997.58M | -6.403 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-12-18 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-11-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-09-15 | Ripresa | Truist | Buy |
| 2025-09-11 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-08-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-07-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-05-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2025-01-17 | Downgrade | Deutsche Bank | Hold → Sell |
| 2024-11-12 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Strong Buy |
| 2024-10-04 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-08-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2024-07-25 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-07-23 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-24 | Downgrade | UBS | Buy → Neutral |
| 2023-07-17 | Ripresa | Evercore ISI | Outperform |
| 2023-06-15 | Iniziato | Societe Generale | Sell |
| 2023-05-31 | Iniziato | UBS | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-14 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | Iniziato | William Blair | Outperform |
| 2022-10-12 | Iniziato | Oppenheimer | Perform |
| 2022-07-29 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | Ripresa | Stifel | Buy |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-28 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-09-23 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | Iniziato | Deutsche Bank | Hold |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-06-18 | Iniziato | UBS | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | Iniziato | Redburn | Neutral |
| 2021-03-05 | Reiterato | H.C. Wainwright | Neutral |
| 2021-02-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-07-29 | Iniziato | H.C. Wainwright | Neutral |
| 2020-02-10 | Iniziato | BofA/Merrill | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-10-31 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | Iniziato | JP Morgan | Overweight |
| 2019-09-27 | Iniziato | Wells Fargo | Market Perform |
| 2019-09-16 | Ripresa | Cowen | Outperform |
| 2019-06-28 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-18 | Ripresa | SunTrust | Buy |
| 2019-01-04 | Iniziato | Morgan Stanley | Overweight |
| 2018-12-17 | Iniziato | Goldman | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-06-29 | Iniziato | Nomura | Buy |
| 2018-04-09 | Iniziato | SunTrust | Buy |
| 2018-01-29 | Reiterato | JMP Securities | Mkt Outperform |
Mostra tutto
Argen X Se Adr Borsa (ARGX) Ultime notizie
Argenx SE Stock: Biotech Leader in Autoimmune Therapies Driving Investor Interest with Strong Growth - AD HOC NEWS
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
ExxonMobil Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
argenx SE (HAM:1AEA) Stock Price, Trades & News - GuruFocus
$100 Invested In argenx 5 Years Ago Would Be Worth This Much Today - Sahm
Argenx SE Stock Faces Pressure Amid Pipeline Setbacks and Market Volatility in Biotech Sector - AD HOC NEWS
Morgan Stanley Upgraded, Tyson Foods Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story - The Motley Fool
Form 6K argenx NV ADR For: 20 March By Investing.com - Investing.com South Africa
Form 6K argenx NV ADR For: 20 March - Investing.com
argenx announces Annual General Meeting of Shareholders on May 6, 2026 - ChartMill
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC), Argenx Se (ARGX) and Erasca (ERAS) - The Globe and Mail
Argenx SE stock faces pressure as Iron Triangle Partners trims position amid biotech sector watchlis - AD HOC NEWS
TD Cowen reiterates argenx stock Buy rating on growth outlook By Investing.com - Investing.com India
TD Cowen reiterates argenx stock Buy rating on growth outlook - Investing.com
Deutsche Bank lifts Argenx to Buy as valuation ’no longer demanding’ - Investing.com South Africa
Deutsche Bank upgrades argenx stock to Buy on valuation appeal By Investing.com - Investing.com South Africa
Deutsche Bank upgrades argenx stock to Buy on valuation appeal - Investing.com India
Forecasting The Future: 16 Analyst Projections For argenx - Sahm
Argenx (ARGX) 2025 Net Product Sales Rise 90% to $4.2B as First Annual Profit Reached - Finviz
Analysts Express Mixed Opinion on Argenx SE (ARGX) Stock - Finviz
Argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline - marketscreener.com
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline - ChartMill
Empowering Investor Success - Morningstar
Argenx Benefits From Strong Growth for Vyvgart; Pipeline Continues to Make Progress - morningstar.com
Oppenheimer raises argenx stock price target to $1,060 on sales growth - Investing.com
RBC Capital Adjusts argenx SE ADR PT to $890 From $925, Maintains Outperform Rating - marketscreener.com
ARGENX : Goldman Sachs gives a Buy rating - marketscreener.com
Citizens raises argenx stock price target on ocular MG results - Investing.com
ARGENX : Deutsche Bank reiterates its Neutral rating - marketscreener.com
argenx Q4 2025 slides: first profitable year, 90% revenue surge By Investing.com - Investing.com Australia
Stifel cuts argenx stock price target to $1,227 on valuation By Investing.com - Investing.com South Africa
Earnings call transcript: Argenx Q4 2025 sees strong earnings beat, stock dips - Investing.com
BofA raises argenx stock price target to $1,013 on trial success - Investing.com
Stifel cuts argenx stock price target to $1,227 on valuation - Investing.com India
argenx Q4 2025 slides: first profitable year, 90% revenue surge - Investing.com South Africa
ARGENX : Gets a Buy rating from Goldman Sachs - marketscreener.com
ARGENX : Barclays reiterates its Buy rating - marketscreener.com
Argenx's Vyvgart Improves Ocular Myasthenia Gravis Symptoms in Late-stage Trial - marketscreener.com
ARGENX : Receives a Buy rating from Bernstein - marketscreener.com
Argenx reports $1.3 billion in Q4 global product net sales - marketscreener.com
Argenx: Positive topline results from phase 3 adapt oculus trial of Vyvgart in oMG - marketscreener.com
argenx ADR earnings beat by $2.07, revenue topped estimates - Investing.com
Argenx Says Phase 3 Study of Ocular Myasthenia Gravis Therapy Met Main Goal - marketscreener.com
Argenx SE FY25 swings to profit as Vyvgart sales double - Investing.com
Argenx SE FY25 swings to profit as Vyvgart sales double By Investing.com - Investing.com India
Argenx SE Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Argenx Reports Higher FY25 Attributable Profit, Operating Income - marketscreener.com
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update - Sahm
Argen X Se Adr Azioni (ARGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.57%
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):